Literature DB >> 20537610

Antihypertensive drug development: current challenges and future opportunities.

Peter U Feig1, Sophie Roy, Robert J Cody.   

Abstract

The growing rate of obesity and diabetes, and an aging population has led to increased demand for new antihypertensive compounds. This review highlights the challenges and opportunities associated with each phase of drug discovery and development of novel antihypertensive agents. Discovery and development starts with identification of a protein hypothesized to be linked to hypertension. Using the information gathered during this early stage, several potential candidates are often synthesized and moved on through preclinical evaluations, eventually leading to selection of one or more compounds for testing in humans. The compounds then enter preclinical safety studies in laboratory animal species and subsequently are tested in tiered clinical studies. As the compounds enter clinical testing, there is an exponential increase in the investment of resources to demonstrate that a new compound is a viable and worthy therapeutic agent for hypertension. The review provides some forecasting of issues that are likely to impact drug development of novel antihypertensives in the future. Copyright (c) 2010 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20537610     DOI: 10.1016/j.jash.2010.04.003

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  6 in total

1.  Novel drugs targeting hypertension revisited.

Authors:  George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2010-09       Impact factor: 3.105

Review 2.  The physiological roles of phosducin: from retinal function to stress-dependent hypertension.

Authors:  Nadine Beetz; Lutz Hein
Journal:  Cell Mol Life Sci       Date:  2010-10-31       Impact factor: 9.261

Review 3.  Methods of Blood Pressure Assessment Used in Milestone Hypertension Trials.

Authors:  Yi Chen; Lei Lei; Ji-Guang Wang
Journal:  Pulse (Basel)       Date:  2018-07-18

Review 4.  The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressure.

Authors:  Quanbin Xu; Dane D Jensen; Hua Peng; Yumei Feng
Journal:  Pharmacol Ther       Date:  2016-04-23       Impact factor: 12.310

5.  Iptakalim: A novel multi-utility potassium channel opener.

Authors:  Pranav Sikka; Seema Kapoor; V K Bindra; Manish Saini; K K Saxena
Journal:  J Pharmacol Pharmacother       Date:  2012-01

6.  Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events.

Authors:  Kejian Wang; Mei Wan; Rui-Sheng Wang; Zuquan Weng
Journal:  J Med Internet Res       Date:  2016-04-01       Impact factor: 5.428

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.